AbbVie beefs up the immunology pipeline, betting up to $865M on a PhII-ready drug — and fueling a biotech stock frenzy

AbbVie’s immunology team is tossing $60 million into the pot being wagered on the lead drug at Mitch Gold’s latest venture.

The Dendreon founder helped make history in immuno-oncology, though not the big money once forecast for Provenge, and set his sights on glory with Seattle-based Alpine Immune Sciences.